Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Leases (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Operating Leases for 6 consecutive years, with $11.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 8.3% year-over-year to $11.6 million, compared with a TTM value of $11.6 million through Sep 2025, up 8.3%, and an annual FY2023 reading of $11.2 million, up 34.18% over the prior year.
  • Operating Leases was $11.6 million for Q3 2025 at Barinthus Biotherapeutics, down from $12.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $12.0 million in Q2 2025 and bottomed at $1.4 million in Q2 2021.
  • Average Operating Leases over 5 years is $8.7 million, with a median of $10.0 million recorded in 2023.
  • The sharpest move saw Operating Leases skyrocketed 500.72% in 2022, then decreased 4.63% in 2024.
  • Year by year, Operating Leases stood at $6.5 million in 2021, then rose by 27.52% to $8.3 million in 2022, then skyrocketed by 34.18% to $11.2 million in 2023, then fell by 4.54% to $10.7 million in 2024, then grew by 8.3% to $11.6 million in 2025.
  • Business Quant data shows Operating Leases for BRNS at $11.6 million in Q3 2025, $12.0 million in Q2 2025, and $11.9 million in Q1 2025.